Nea Management Company, Llc
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$1.76B
Q ending 2026-03-31
Prior quarter
$1.96B
Q ending 2025-12-31
Change
-10.3% QoQ · +35.5% YoY
Positions
26
reported holdings
Largest positions
All 26 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Arcellx, Inc. | ACLX | Shares | $349.7M | 3.0M |
| Celcuity Inc. | CELC | Shares | $260.9M | 2.3M |
| Spyglass Pharma, Inc. | SGP | Shares | $191.5M | 7.4M |
| Trevi Therapeutics, Inc. | TRVI | Shares | $157.7M | 13.2M |
| Savara, Inc. | SVRA | Shares | $133.6M | 24.5M |
| Monte Rosa Therapeutics, Inc. | GLUE | Shares | $126.5M | 7.7M |
| Mbx Biosciences, Inc. | MBX | Shares | $107.9M | 3.6M |
| Zenas Biopharma, Inc. | ZBIO | Shares | $78.7M | 4.0M |
| Coursera, Inc. | COUR | Shares | $74.9M | 12.9M |
| Aurinia Pharmaceuticals, Inc. | AUPH | Shares | $58.8M | 4.0M |
| Oric Pharmaceuticals, Inc. | ORIC | Shares | $52.2M | 4.1M |
| Crispr Therapeutics Ag | Shares | $50.4M | 1.1M | |
| Phathom Pharmaceuticals, Inc. | PHAT | Shares | $21.8M | 2.0M |
| Cvrx, Inc. | CVRX | Shares | $19.2M | 2.0M |
| Korro Bio, Inc. | KRRO | Shares | $14.7M | 1.3M |
| X4 Pharmaceuticals, Inc. | ASNSUSD | Shares | $13.4M | 3.2M |
| Champions Oncology, Inc. | CSBR | Shares | $9.9M | 1.7M |
| Black Diamond Therapeutics, Inc. | BDTX | Shares | $9.5M | 4.4M |
| Inventiva Sa | IVA | Shares | $8.0M | 1.5M |
| Nkarta, Inc. | NKTX | Shares | $7.5M | 3.6M |
| Leonabio, Inc. | LONA | Shares | $4.8M | 464K |
| Senti Biosciences, Inc. | Shares | $3.1M | 3.8M | |
| Marker Therapeutics, Inc. | MRKR | Shares | $2.1M | 1.6M |
| Onkure Therapeutics, Inc. | OKUR | Shares | $2.0M | 479K |
| Gossamer Bio, Inc. | GOSS | Shares | $329K | 1.0M |
| Imagenebio, Inc. | IMA | Shares | $250K | 50K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.